Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.

Kenvue Inc. (NYSEKVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.

Elf Beauty appeared to rally along with KVUE on Monday.

Haleon (HLN​​​​​​​) is one of the largest consumer health companies in the world. Over the past year, Haleon PLC share price rose 13.8% from $7.60 to $8.66 as of Tuesday’s market close.

Companies Reporting Before The Bell • Frontline (NYSEFRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on innovative medicines and vaccines.

Pfizer Inc. (NYSEPFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE NASDAQ: BNTXNASDAQBNTX)

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks arrange debt financing for potential buyers.

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth areas.

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.

Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced that its subsidiary Dr. Reddy's Laboratories SA has signed a definitive agreement with Haleon plc (LSE/NYSE: HLN; “Haleon”), a leading consumer healthcare company, for purchase of shares of Northstar Switzerland SARL, a Haleon group company, to acquire Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (“NRT”) category outside of the United States. The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.

Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial discipline, a £500 million share buyback plan for 2024, and reaffirms 2024 growth targets.

A Robitussin recall is underway for two of the company's products after discovering microbial contamination of its cough syrups.

Haleon PLC (NYSEHLN) announced a product recall of some of its Robitussin brand cough syrups. What Happened: A microbial contamination in Robitussin cough syrups could potentially cause life-threatening events in immunocompromised customers.

GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.